BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12635453)

  • 1. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
    Jun JK; Gong WC; Mathur R
    Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
    [No Abstract]   [Full Text] [Related]  

  • 2. Actos (pioglitazone): a new treatment for type 2 diabetes.
    Lawrence JM; Reckless JP
    Hosp Med; 2001 Jul; 62(7):411-6. PubMed ID: 11480129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
    King AB
    Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
    Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
    Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
    King AB; Armstrong DU
    Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
    LaCivita KA; Villarreal G
    Curr Med Res Opin; 2002; 18(6):363-70. PubMed ID: 12442884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
    Pan C; Gao Y; Gao X; Li G; Luo B; Shi H; Tian H; Jia P; Lin H; Xing X; Zhao Y; Zhou L
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):388-92. PubMed ID: 12137601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
    Nakamura T; Ushiyama C; Osada S; Shimada N; Ebihara I; Koide H
    Ren Fail; 2001 Nov; 23(6):863-4. PubMed ID: 11777327
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.
    de Rivas B; Luque M; Martell N; Fernández C; Fernández-Cruz A
    J Clin Hypertens (Greenwich); 2007 Jul; 9(7):530-7. PubMed ID: 17617763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy of Pioglitazone (AD-4833)].
    Kaneko T; Baba S
    Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
    [No Abstract]   [Full Text] [Related]  

  • 14. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
    Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular effects of troglitazone.
    Umland EM; Romanelli AM
    Ann Pharmacother; 1999 Feb; 33(2):229-32. PubMed ID: 10084419
    [No Abstract]   [Full Text] [Related]  

  • 16. Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes.
    Shimono D; Kuwamura N; Nakamura Y; Koshiyama H
    Diabetes Care; 2001 May; 24(5):971. PubMed ID: 11347775
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of pioglitazone in modifying the atherogenic lipoprotein profile.
    Hanefeld M
    Diabetes Obes Metab; 2009 Aug; 11(8):742-56. PubMed ID: 19519869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone (Actos).
    Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA approves pioglitazone for diabetes.
    Miller JL
    Am J Health Syst Pharm; 1999 Sep; 56(17):1698. PubMed ID: 10512494
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.